Table 1 Clinical characteristics of the patients after HSCT with PT

Time of evaluation (post-HSCT)

100 (80–150)

121 (87–149)

.078

Age at HSCT, median (range), year

27 (11–56)

26 (3–58)

.959

Gender (male/female)

22/12

15/11

.603

PLT count (×10⁹/L)

33.68 (12–83)

143.38 (100–219)

<.001

Disease type

 Acute Leukemia

20

14

.095

 Other

21

5

Source of stem cell

 BM and PB

29

25

.221

 PB

5

1

Transplanted total nucleated cell dose, ×10⁸/kg

7.195 (5.00–10.10)

6.905 (3.44–9.12)

.350

Transplanted CD34+ cells, ×10⁶/kg

1.925 (0.73–7.42)

2.465 (0.38–4.47)

.685

Donor type

 HLA partially matched related donor

26

19

.689

 Unrelated donor

2

1

 Identical sibling

6

6

Status at HSCT

 Standard risk

26

20

.999

 High risk

8

6

Conditioning regimen

 BU/CY + ATG

27

19

.239

 BU/CY

4

7

 TBI

3

0

History of severe GvHD

21

8

.021

History of CMV reactivation

26

12

.029